229 related articles for article (PubMed ID: 21887697)
1. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
3. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
4. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Chik F; Machnes Z; Szyf M
Carcinogenesis; 2014 Jan; 35(1):138-44. PubMed ID: 23985780
[TBL] [Abstract][Full Text] [Related]
7. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
Pakneshan P; Szyf M; Rabbani SA
Carcinogenesis; 2005 Mar; 26(3):557-64. PubMed ID: 15618232
[TBL] [Abstract][Full Text] [Related]
8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
10. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
11. High levels of uPA and PAI-1 predict a good response to anthracyclines.
Borstnar S; Sadikov A; Mozina B; Cufer T
Breast Cancer Res Treat; 2010 Jun; 121(3):615-24. PubMed ID: 20039121
[TBL] [Abstract][Full Text] [Related]
12. Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Mol Cell Probes; 2010 Apr; 24(2):87-92. PubMed ID: 19837153
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C
Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulators combination with chemotherapy in breast cancer cells.
Ari F; Napieralski R; Akgun O; Magdolen V; Ulukaya E
Cell Biochem Funct; 2021 Jun; 39(4):571-583. PubMed ID: 33608886
[TBL] [Abstract][Full Text] [Related]
15. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
16. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Guo Y; Pakneshan P; Gladu J; Slack A; Szyf M; Rabbani SA
J Biol Chem; 2002 Nov; 277(44):41571-9. PubMed ID: 12198113
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
[TBL] [Abstract][Full Text] [Related]
18. PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression.
Luparello C; Sirchia R; Pupello D
J Cell Sci; 2003 Jun; 116(Pt 12):2421-30. PubMed ID: 12724357
[TBL] [Abstract][Full Text] [Related]
19. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
20. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
